Obecabtagene autoleucel at a glance
Medicine class
CD19-directed autologous CAR T-cell and gene therapy
Licensed use
Relapsed or refractory B-cell precursor acute lymphoblastic leukaemia in adults
How it is made
Manufactured specifically for each patient from their collected T cells
Administration
Given intravenously in a qualified specialist treatment centre
What is Obecabtagene autoleucel used for?
The licensed indication is:
Adults with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia.
How does Obecabtagene autoleucel work?
The patient’s T cells are modified with a receptor that binds CD19 on leukaemia cells and normal B cells. This activates the T cells, helping them multiply and kill CD19-expressing cells. Temporary or prolonged loss of normal B cells can also occur.
How to take Obecabtagene autoleucel
This treatment is not taken at home. The patient’s T cells are collected and modified in a laboratory. After preparatory chemotherapy, the patient-specific product is infused into a vein by a trained specialist team.
The patient’s identity must match the infusion certificate and product labels.
Remain near the qualified treatment centre for at least four weeks after the first infusion and attend all monitoring appointments.
Carry the supplied patient card and show it to healthcare professionals.
Do not drive or operate dangerous machinery for at least eight weeks after infusion, or longer if neurological symptoms persist.
Do not donate blood, organs, tissues or cells for transplantation.
Obecabtagene autoleucel side effects
Common or expected effects
- Cytokine release syndrome, often involving fever, low blood pressure or low blood oxygen
- Infections
- Reduced red cells, white cells or platelets
- Fever, fatigue, pain or swelling
- Headache, dizziness or altered brain function
- Nausea, vomiting, diarrhoea, constipation or abdominal pain
- Cough, reduced appetite, rash or musculoskeletal pain
- Fast heartbeat
Get urgent medical advice
- Cytokine release syndrome causing fever, breathing difficulty, low blood pressure or organ problems
- Neurotoxicity causing confusion, speech difficulty, tremor, seizures or reduced consciousness
- Severe or opportunistic infection
- Serious bleeding or severe, prolonged reduction in blood-cell counts
- Severe allergic reaction, including anaphylaxis related to dimethyl sulfoxide
- Tumour lysis syndrome
- Haemophagocytic lymphohistiocytosis or macrophage activation syndrome
- Secondary malignancy, including reported T-cell malignancies following this therapy class
Obecabtagene autoleucel in pregnancy
Pregnancy must be excluded before treatment. Evidence is limited, and fetal harm—including loss of fetal B cells—is possible if modified cells cross the placenta, so use during pregnancy is not recommended. Pregnancy after treatment must be discussed with the specialist; assessment of the newborn’s B cells and immunoglobulins may be needed.
Obecabtagene autoleucel while breastfeeding
It is unknown whether modified cells enter human milk or can reach a breastfed child. Anyone breastfeeding or considering breastfeeding should discuss the potential risk with the specialist CAR T-cell team.
Obecabtagene autoleucel interactions
Formal interaction studies have not been performed. The specialist team should review all medicines, vaccines and complementary products.
Systemic corticosteroids
Preventive use before infusion may interfere with CAR T-cell activity, although corticosteroids may be required to treat serious treatment-related toxicity.
Live viral vaccines
Avoid before preparatory chemotherapy, during treatment and until immune recovery because safety has not been established.
Immunomodulatory herbal remedies
Interactions have not been formally studied. Disclose all herbal products and follow specialist advice.
Common questions about Obecabtagene autoleucel
Answers are fully visible for fast scanning and source review.
Is this treatment made from donor cells?
No. It is manufactured specifically from the intended patient’s own collected T cells and must never be given to anyone else.
Why is chemotherapy given beforehand?
Preparatory lymphodepleting chemotherapy reduces existing white cells, creating conditions that help the modified T cells expand after infusion.
What is cytokine release syndrome?
It is an inflammatory reaction caused by immune activation. Signs may include fever, low blood pressure, low blood oxygen, breathing difficulty, nausea, diarrhoea, fatigue or organ problems and require immediate assessment.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.